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 Fstl1, also known as transforming growth
factor-b–stimulated clone 36, is an extra-
cellular glycoprotein implicated in the
pathophysiology of cardiac disease.
 Fstl1 acts in a noncanonical manner
relative to other follistatin family
members, but its functions remain poorly
understood.
 Circulating Flst1 levels are increased in
humans with chronic stable HFpEF.
 Fstl1 treatment modulates cardiomyocyte
hypertrophy in vitro and in vivo.
 Cardiac myocyte deletion of Fstl1
worsens the HFpEF phenotype in mice.
 These studies indicate that Fstl1 may be
therapeutically effective in HFpEF by
modulating cardiac hypertrophy and
improving parameters of diastolic
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ABBR EV I A T I ON S
AND ACRONYMS
ANP = atrial natriuretic pep
ARVM = adult rat ventricu
myocytes
BNP = brain natriuretic pep
BP = blood pressure
Fstl1 = follistatin-like 1
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
reduced ejection fraction
HR = heart rate
HTN = hypertension
IVST = interventricular sep
wall thickness
LV = left ventricular
LVEDD = left ventricular
end-diastolic diameter
LVEF = left ventricular ejec
fraction
LVH = left ventricular
hypertrophy
LVPWT = left ventricular
posterior wall thickness
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tioHeart failure with preserved ejection fraction (HFpEF) accounts for w50% of all clinical presentations of heart failure,
(HF) and its prevalence is expected to increase. However, there are no evidence-based therapies for HFpEF; thus, HFpEF
represents a major unmet need. Although hypertension is the single most important risk factor for HFpEF, with a
prevalence of 60% to 89% from clinical trials and human HF registries, blood pressure therapy alone is insufﬁcient to
prevent and treat HFpEF. Follistatin-like 1 (Fstl1), a divergent member of the follistatin family of extracellular
glycoproteins, has previously been shown to be elevated in HF with reduced ejection fraction and associated with
increased left ventricular mass. In this study, blood levels of Fstl1 were increased in humans with HFpEF. This increase
was also evident in mice with hypertension-induced HFpEF and adult rat ventricular myocytes stimulated with aldo-
sterone. Treatment with recombinant Fstl1 abrogated aldosterone-induced cardiac myocyte hypertrophy, suggesting a
role for Fstl1 in the regulation of hypertrophy in HFpEF. There was also a reduction in the E/A ratio, a measure of diastolic
dysfunction. Furthermore, HFpEF induced in a mouse model that speciﬁcally ablates Fstl1 in cardiac myocytes (cardiac
myocyte-speciﬁc Fstl1 knockout [cFstl1-KO]) showed exacerbation of HFpEF with worsened diastolic dysfunction. In
addition, cFstl1-KO-HFpEF mice demonstrated more marked cardiac myocyte hypertrophy with increased molecular
markers of atrial natriuretic peptide and brain natriuretic peptide expression. These ﬁndings indicate that Fstl1 exerts
therapeutic effects by modulating cardiac hypertrophy in HFpEF. (J Am Coll Cardiol Basic Trans Science 2016;1:207–21)
© 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).H eart failure with preserved ejection fraction(HFpEF) accounts for up to 50% of all heartfailure (HF) presentations (1); yet, in
contrast to heart failure with reduced ejection frac-
tion (HFrEF), there are no evidence-based therapies.
The numerous negative or neutral HFpEF clinical
trials, to date, suggest an incomplete mechanistice
e
nunderstanding about HFpEF and the comor-
bidities that are ubiquitous in HFpEF (2,3).
Therefore, the increasing prevalence of this
disease and the failure to identify successful
therapies for HFpEF suggest that the identiﬁ-
cation of novel pathways is a priority.SEE PAGE 222Despite associated comorbidities, such as
obesity and diabetes mellitus, hypertension
(HTN) remains the most important risk factor
for HFpEF, with a prevalence of 60% to 89%
reported in large controlled trials, epidemio-
logical studies, and HF registries (1). The
presence of left ventricular hypertrophy
(LVH) plays a major pathophysiological role
in HFpEF, particularly when associated with
HTN (4). Myocardial biopsies obtained from a
highly selected, younger patient population
with HFpEF demonstrated cardiac myocyte
hypertrophy, interstitial ﬁbrosis, and evi-
dence of systemic and myocardial inﬂam-
mation, and oxidative stress (5,6). Therefore,
an improved understanding of the HFpEF
phenotype, particularly LVH, may provideinsights into the development of new therapies for
the treatment of HFpEF (7).
Follistatin-like 1 (Fstl1), also known as trans-
forming growth factor-betastimulated clone 36, is
an extra-cellular glycoprotein that was originally
cloned from a mouse osteoblastic cell line as a
transforming growth factor-betainducible gene and
is highly conserved across species (8). Fstl1 acts in a
noncanonical manner relative to other follistatin
family members. However, its functions remain
poorly understood and are possibly cell-type speciﬁc.
Transduction of Fstl1 into cancer cell lines suppresses
growth and invasion (9). Fstl1 is reported to have both
anti-inﬂammatory (10) and proinﬂammatory (11)
actions. Recent studies also implicate Fstl1 in the
pathophysiology of cardiac disease in several murine
models. Fstl1 overexpression minimized ischemia-
reperfusion injury and diminished apoptosis (12).
Similarly, Fstl1 improved endothelial cell function
and revascularization in a hind-limb ischemia model
(13). Recently, we demonstrated elevated blood levels
of Fstl1 in a cohort of humans with chronic, stable
HFrEF; where elevated Fstl1 levels were signiﬁcantly
associated with LV mass and circulating brain natri-
uretic peptide (BNP) levels, suggesting a pathogenic
role for Fstl1 in cardiac remodeling and LVH (14). In
patients with HFpEF, more often than not, structural
changes such as LVH are present, because HTN is a
major risk factor for the development of LVH (1).
We previously utilized a murine model of HFpEF,
which demonstrates features consistent with HFpEF
in humans (15–17). HFpEF mice exhibit exercise
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209intolerance (one of the earliest symptoms of HFpEF
in humans), moderate HTN, pulmonary congestion,
diastolic dysfunction, and LVH with preserved left
ventricular ejection fraction (LVEF). In the present
study, we sought to determine whether Fstl1 plays a
role in the regulation of cardiac hypertrophy in
HFpEF.
METHODS
IN VIVO MURINE MODEL. The Institutional Animal
Care and Use Committee at Boston University School
of Medicine approved all study procedures related to
the handling and surgery of the mice.
Exper imenta l model . Cardiac myocyte-speciﬁc
Fstl1 knockout (cFstl1-KO) mice in an FVB back-
ground were generated as previously described (18).
Brieﬂy, mice with loxP sites ﬂanking the exon 1 of the
Fstl1 gene (Fstl1ﬂox/ﬂox) were crossed with mice
overexpressing Cre recombinase under the control of
the a-myosin heavy chain promoter (The Jackson
Laboratory, Bar Harbor, Maine). 10- to 12-week-old
male/female cFstl1-KO mice and their wild-type (WT)
littermates were anesthetized with 80 to 100 mg/kg
ketamine and 5 to 10 mg/kg xylazine intraperitone-
ally. All mice underwent uninephrectomy and
received either a continuous infusion of saline (Sham)
or d-aldosterone (0.15 mg/h, Sigma-Aldrich Co., St.
Louis, Missouri) (HFpEF) for 4 weeks via osmotic
minipumps (Alzet, Durect Corp., Cupertino, Califor-
nia) (16). All mice were maintained on standard ro-
dent chow and 1.0% sodium chloride drinking water.
The 4 groups studied were: WT mice infused with
saline (WT-Sham); cFstl1-KO mice infused with
saline (cFstl1-KO-Sham); WT mice infused with
d-aldosterone (WT-HFpEF); and cFstl1-KO mice
infused with d-aldosterone (cFstl1-KO-HFpEF). Mice
were randomly assigned to each experimental group.
Phys io log ica l measurements . Heart rate (HR) and
blood pressure (BP) were measured weekly using a
noninvasive tail-cuff blood pressure analyzer (BP-
2000 Blood Pressure Analysis System, Visitech Sys-
tems, Inc., Apex, North Carolina). After 4 weeks of
saline or d-aldosterone infusion, transthoracic echo-
cardiography was performed using the Vevo 770
High-Resolution In Vivo Micro-Imaging System and a
Real-Time Micro Visualization 707B Scanhead
(VisualSonic Inc., Toronto, Ontario, Canada), as pre-
viously described (16). Brieﬂy, to assess diastolic
function, mice were anesthetized with isoﬂurane
(0.5% for induction followed by 0.5% to 1.5% for
maintenance) and maintained at an HR of w350
beats/min, because diastolic function is sensitive to
HR and loading conditions. The maximum dose ofisoﬂurane had minimal effects on diastolic function
(16,19). Pulse wave measurements were recorded.
Interventricular septum wall thickness (IVST), LV
posterior wall thickness (LVPWT), LV end-diastolic
diameter (LVEDD), LV end-systolic diameter, and
LVEF were obtained. Total wall thickness was derived
from an average of the IVST and LVPWT. LV mass was
calculated using the formula: LV mass ¼ 1.05 
[(LVEDD þ IVST þ PWT)3  (LVEDD)3], as described by
Kiatchoosakun et al. (20). After these measurements,
mice were sacriﬁced, and the ratio of wet to dry lung
weight was used as an indicator of pulmonary
congestion.
Adenov i ra l vector exper iments . Another group of
WT mice underwent the same surgical procedures as
outlined in the previous text. Fourteen days after
surgery, mice were injected in the jugular vein
with 1  109 plaque-forming units of adenoviral con-
structs encoding Fstl1 (Ad-Fstl1) or expressing
b-galactosidase (Ad-bgal): 1) WT-saline plus Ad-bgal;
2) WT-aldosterone plus Ad-bgal; 3) WT-saline plus
Ad-Fstl1; and 4) WT-aldosterone plus Ad-Fstl1. After
14 days, analyses were performed and then mice were
killed. Prior studies showed that this adenovirus de-
livery model led to transduction of Fstl1 in the liver
but not the heart, thereby allowing the assessment of
the cardioprotective properties of the secreted form
of Fstl1 (12,21).
Serum aldosterone. After mice were sacriﬁced,
blood was obtained to determine serum aldosterone
levels using an enzyme immunoassay (Alpha Diag-
nostic Intl. Inc., San Antonio, Texas) (16).
Histopatho log ica l ana lys i s . Parafﬁn-embedded
sections of the midventricle (5 mm) were stained with
hematoxylin and eosin and Masson trichrome stain-
ing to assess LV cardiac myocyte cross-sectional area
and myocardial ﬁbrosis as previously described (16).
These sections were analyzed, blinded to group
identity. Fstl1 staining was assessed as previously
described (18). Digital images of stained sections were
acquired using an Olympus BX41 Clinical Microscope
(Olympus America Inc., Center Valley, Pennsylvania)
and analyzed using ImageJ (National Institutes of
Health, Bethesda, Maryland).
RNA isolat ion and quant i tat ive rea l - t ime
PCR. Total RNA was extracted, and cDNA was syn-
thesized as previously described (16). qRT-PCR was
performed with SYBR Green PCR Master Mix (Life
Technologies Corporation, Carlsbad, California) in a
ViiA7 PCR system (Life Technologies Corporation).
Primer sequences are shown in Table 1.
Western blot ana lys i s . Protein extraction and
western blot analysis were performed as described
previously (16,22).
TABLE 1 Primer Sequences Used in qRT-PCR
Forward Reverse
Mouse ANP ATCTGCCCTCTTGAAAAGCA AAGCTGTTGCAGCCTAGTCC
Mouse BNP GTCCAGCAGAGACCTCAAAA AGGCAGAGTCAGAAACTGGA
Mouse collagen 1 CAGAAGATGTAGGAGTCGAG GGACCCAAGGGAGACCCTGG
Mouse collagen 3 GTGGACTGCCTGGACCTCCA GGTATCAAAGGCCCAGCTGG
Mouse Fstl1 AACAGCCATCAACATCACCACTTAT TTTCCAGTCAGCGTTCTCATCA
Mouse GAPDH CCAAGGTCATCCATGACAACT GGGCCATCCACAGTCTTCT
Rat ANP GCTGCTTTGGGCAGAAGATA AGAGTCTGCAGCCAGGAGGT
Rat GAPDH CTGCACCACCAACTGCTTAG CTTCTGAGTGGCAGTGATGG
ANP ¼ atrial natriuretic peptide; BNP ¼ brain natriuretic peptide; GAPDH ¼ glyceraldehyde 3-phosphate
dehydrogenase.
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210HUMAN STUDIES. Written informed consent was ob-
tained from all participants prior to the collection of
clinical samples. The study was approved by the
Boston University Medical Center Institutional Re-
view Board and conducted according to Declaration
of Helsinki principles.
Subjects . Control subjects were healthy, without HF
or known cardiac disease (n ¼ 8). They had normal BP
and were not taking cardiovascular medications. Pa-
tients with HFpEF were enrolled from the outpatient
HF Clinic at Boston Medical Center (n ¼ 32). Patients
with stable HFpEF were included if they were previ-
ously admitted with HF to an inpatient HF service
within the prior year and had an LVEF >50% as
measured by echocardiogram within 6 months prior
to enrollment. Echocardiographic evaluation deter-
mined structure and chamber dimensions. Patients
with inﬁltrative disease (e.g., amyloid), a genetic
cardiomyopathy (e.g., hypertrophic obstructive car-
diomyopathy), or a family history of sudden cardiac
death and restrictive disease (e.g., constrictive peri-
carditis) were excluded. HFpEF etiology was deﬁned
as: 1) hypertensive: documented history of pharma-
cologically treated HTN; 2) ischemic: prior history of
myocardial infarction (electrocardiogram/positive
troponin), results of a positive noninvasive stress
test, or cardiac catheterization; and 3) unknown:
having no identiﬁable cause of the cardiomyopathy.
New York Heart Association functional classiﬁcation,
a functional assessment of HF symptoms, was deter-
mined (1).
Serum samples were obtained in the outpatient
clinic from hemodynamically stable patients with
HFpEF who had no evidence of acute decompensa-
tion or acute renal failure. After informed consent,
blood samples were obtained using routine veni-
puncture procedure. Samples were centrifuged at
2,000 g for 15 min within 1 h from collection. Serum
samples were then aliquoted and stored at 80C.Serum Fst l 1 . Total circulating levels of Fstl1 were
measured in serum samples by enzyme-linked
immunoassay according to the manufacturer’s in-
structions (USCN Life Science Inc., Wuhan, Hubei,
China). Standard, controls, and samples were
measured in triplicate and averaged. The protein
concentrations were calculated using a standard
curve generated with recombinant standards pro-
vided by the manufacturer. We performed a spike and
recovery assay to verify that the enzyme-linked
immunosorbent assay did not cross-react with
related proteins, such as follistatin or follistatin-
like 3.
Laboratory va lues . BNP and cardiac troponin I (TnI)
were measured as part of routine laboratory testing.
Echocard iography . Both 2-dimensional and Doppler
echocardiography were performed as previously
described (14) using the Vingmed Vivid Five System
(GE Healthcare) with a 2.5-Mhz phased-array trans-
ducer. Echocardiogramswere performed and analyzed
in a blinded manner. Measurements of systolic and
diastolic chamber dimensions and wall thickness were
obtained from 2-dimensional imaging according to the
recommendations of the American Association of
Echocardiography (23,24). The standard cube formula
was utilized to calculate LV mass. Relative wall thick-
ness was calculated as: (2  LVPWT) / LVEDD.
IN VITRO STUDIES. I so lat ion and treatment of
adult rat card iac myocytes . Primary cultures of
adult rat ventricular cardiac myocytes (ARVM) were
prepared as described previously (22,25). ARVM were
pre-treated with or without 100 ng/ml recombinant
human Fstl1 protein (rFstl1) for 30 min and were then
treated with d-aldosterone (Sigma-Aldrich Co.).
Preparation of recombinant human Fstl1 protein. rFstl1
tagged with FLAG in the N terminus was prepared in
Sf9 cells with minor modiﬁcations of the procedure as
previously described (26).
[ 3H]- leuc ine incorporat ion assay . Protein syn-
thesis as an indication of cardiac myocyte hypertro-
phy was measured using a [3H]-leucine incorporation
assay (22).
STATISTICAL ANALYSIS. Statistical signiﬁcance of
differences between the 2 groups was assessed by 2-
tailed unpaired Student t tests. One-way ANOVA
and the Newman-Keuls post-hoc test were used to
test for differences among at least 3 groups. In cases
where the data was not normally distributed, a
Kruskal-Wallis test followed by a Dunn test was used.
A p value #0.05 was considered statistically signiﬁ-
cant. All statistical analyses were performed using
GraphPad Prism (GraphPad Software, Inc. La Jolla,
California).
FIGURE 1 Fstl1 Levels Are Increased in HFpEF
(A) Follistatin-like 1 (Fstl1) serum levels in patients with heart failure with preserved ejection fraction (HFpEF) (n ¼ 32) versus control subjects
(Control) (n ¼ 8). (B) Fstl1 protein levels in adult rat cardiac myocytes (ARVM) stimulated with aldosterone (Aldo) 1 mmol/l (n ¼ 5 per group).
(C) Fstl1 mRNA and (D) protein levels and representative immunohistochemistry of Fstl1 staining in the left ventricle of Sham (E) and
HFpEF (F) mice (n ¼ 5 to 7 mice/group). Black arrows in E and F indicate Fstl1 staining. Data are mean  SEM. Statistical analysis by 2-tailed
Student t test. GAPDH ¼ glyceraldehyde 3-phosphate dehydrogenase.
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TABLE 2 Characteristics of Ambulatory, Stable Patients
With HFpEF
Values
Normal
Values
Clinical characteristics
Age, yrs 65  2
Male/female 45/55
Race
White 23
Black 74
Other (Asian,
unknown, Hispanic)
3
Etiology of HFpEF
Ischemic 3
Hypertensive/
nonischemic/unknown
97
Comorbidities
Obesity: body mass
index >30 kg/m2
90
Hypertension 90
Type 2 diabetes mellitus 58
Systolic blood pressure, mm Hg 129  26
Diastolic blood pressure, mm Hg 75  10
Heart rate, beats/min 79  2
QRS duration, ms 103  24
NYHA functional class 2.1  0.1
Echocardiography
LVEF, % 63  1
IVS, mm 11.5  0.5 7–11
PW, mm 11.3  0.4 6–11
LVEDD, mm 45.5  1.1 <57
LVESD, mm 31  13 21–40
RWT 0.50  003 0.22–0.42
LV mass, g 187.5  9 67–162
LAVI, ml/m2 38.1  5 16–34
Diastolic function
Normal 32
Grade I diastolic dysfunction 42
Grade 2 diastolic dysfunction 23
Grade 3 diastolic dysfunction 3
Laboratory values
Cardiac TnI, mg/ml 0.025  0.005 <0.033
BNP, pg/ml 242  47 <100
Creatinine, mg/dl 1.44  0.13 0.7–1.3
MDRD eGFR, ml/min/1.73 m2 51.6  2.6 >60
Sodium, mmol/l 139  0.8 135–145
Glucose, mg/dl 136  15 70–100
Values are mean  SD for continuous variables or numbers or percent (%) for
categorical variables. Normal values represent normals from 2D echocardiographic
parameters and standard normal values for routine laboratory. Grade I diastolic
dysfunction: impaired relaxation; grade 2 diastolic dysfunction: pseudonormal
ﬁlling pattern; and grade 3 diastolic dysfunction: reversible restrictive ﬁlling
pattern.
BNP ¼ brain natriuretic peptide; IVS ¼ intraventricular septal thickness;
LAVI ¼ left atrial volume index; LV ¼ left ventricular; LVEDD ¼ left ventricular
end-diastolic diameter; LVEF ¼ left ventricular ejection fraction; LVESD ¼ left
ventricular end-systolic diameter; MDRD eGFR ¼ glomerular ﬁltration rate by
Modiﬁcation of Diet in Renal Disease equation; NYHA ¼ New York Heart Asso-
ciation; PW ¼ posterior wall thickness; RWT ¼ relative wall thickness;
TnI ¼ troponin I.
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Fstl1 LEVELS ARE INCREASED IN PATIENTS WITH
CHRONIC STABLE HFpEF. Similar to our prior ﬁnd-
ings in HFrEF (14), we observed elevated Fstl1 levels
in patients with chronic, stable HFpEF compared
with control subjects (167.2  14.0 ng/ml vs. 95.6 
16.0 ng/ml; p ¼ 0.018) (Figure 1A). A total of 74% of
the patients were black and 55% were women, and
patients had associated comorbidities such as HTN
(90%), obesity (90%), and diabetes mellitus (58%).
LVEF was preserved (63  1%) with mean LV mass
of 187.5  9.1 g (normal <162 g). Mean New York
Heart Association functional class was 2.1  0.1 at
the time of enrollment (Table 2). Diastolic dysfunc-
tion was present in 68% of these patients with
HFpEF. This cohort of HFpEF patients was similar
to those recruited for the I-PRESERVE (Irbesartan in
HFpEF trial), in which 69% of patients had evidence
of diastolic dysfunction before medication random-
ization (27).
CARDIAC MYOCYTE STRESS INDUCES Fstl1
EXPRESSION. Cardiac conditions such as HTN or
myocardial infarction and neurohormonal activation
(e.g., angiotensin II and endothelin) may induce car-
diac myocyte hypertrophy (28). Although initially
compensatory, if the stressor remains unchecked it
may result in decompensated cardiac hypertrophy,
with LV dilation, contractile dysfunction, and subse-
quent clinical HF (29). Because aldosterone stimula-
tion of ARVM induces a stress phenotype (30,31), we
investigated whether cardiac myocytes treated with
aldosterone induced changes in Fstl1 expression
in vitro. ARVM stimulated with a pathophysiological
dose (30) of aldosterone (1 mmol/l for 18 h) increased
Fstl1 expression (p ¼ 0.032) (Figure 1B).
Next, we sought to establish if the ﬁndings seen in
humans with HFpEF and ARVM could be recapitu-
lated in a murine model of HFpEF (15,16,32). As pre-
viously reported, chronic aldosterone infusion
caused HFpEF in mice, with moderate HTN, LVH,
pulmonary congestion, and echocardiographic evi-
dence of diastolic dysfunction, while maintaining a
preserved LVEF (15,16,32). Fstl1 mRNA and protein
expression in the LV of mice with HFpEF were
increased 2-fold (p ¼ 0.001 and p ¼ 0.005 vs. Sham
mice, respectively) (Figures 1C and 1D). This was
conﬁrmed with immunostaining, which showed
marked staining of Fstl1 in the LV of HFpEF
compared with Sham mice (Figures 1E and 1F). These
results thus showed that Fstl1 expression is
expressed and up-regulated during cardiac myocyte
stress and HFpEF.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 4 , 2 0 1 6 Tanaka et al.
J U N E 2 0 1 6 : 2 0 7 – 2 1 Fstl1 and LVH in HFpEF
213Fstl1 MODULATES CARDIAC HYPERTROPHY IN VITRO AND
IN VIVO. Given the increased LV expression of Fstl1 in
mice with HFpEF, we next examined whether Fstl1
had a direct effect on cardiac myocyte hypertrophy.
ARVM were pre-treated with recombinant Fstl1 pro-
tein (rFstl1, 100 ng/ml for 30 min) and then stimu-
lated with aldosterone (1 mmol/l for 18 h). At the
cellular level, cardiac myocyte hypertrophy is char-
acterized by an increase in cell size and enhanced
protein synthesis (7). Thus, to assess cardiac myocyte
hypertrophy, protein synthesis was measured by
[3H]-Leucine incorporation assay. As showed in
Figure 2A, aldo signiﬁcantly increased [3H]-Leucine
incorporation by 2.6-fold compared with control (p <
0.001). This increase was completely abrogated by
rFstl1 pre-treatment (p < 0.001 vs. aldosterone
alone). In ARVM, aldosterone also increased ANP
gene expression, a molecular marker of cardiac
myocyte hypertrophy (33) (p < 0.01 vs. control)
(Figure 2B), and similarly, pre-treatment with rFstl1
decreased ANP expression by 34% in response to
aldosterone (p < 0.001). These results are similar to
prior ﬁndings in neonatal rat ventricular myocyte
showing that Fstl1 attenuates the increase in cell
surface area induced by phenylephrine (18).
We next investigated if the observed in vitro
effects were reproducible in vivo. To examine
whether adenovirus-Fstl1 (Ad-Fstl1) supplementation
decreased cardiac hypertrophy in HFpEF mice,
both WT-aldosterone (HFpEF) and WT-saline (Sham)
mice were treated with either Ad-Fstl1 (1  109FIGURE 2 Treatment With Fstl1 Decreases Cardiac Myocyte Hypertr
(A) 3H-Leucine incorporation and (B) atrial natriuretic peptide (ANP) mR
pre-treatment with 100 ng/ml recombinant human Fstl1 protein (rFstl1)
samples/group. Data are mean  SEM. Statistical analysis by Kruskal-Wplaque-forming units) or Ad-b-galactosidase (Ad-
bgal), which was injected intravenously 14 days after
surgery. Neither Ad-Fstl1 nor Ad-bgal had an effect on
systolic BP in Sham or HFpEF mice (data not shown).
Treatment with Ad-Fstl1 signiﬁcantly reduced cardiac
hypertrophy in HFpEF, as assessed by the heart
weight to body weight ratio, when compared with Ad-
bgal (4.75  0.04 mg/g vs. 5.27  0.17 mg/g; p < 0.01).
Ad-Fstl1 had no effect on heart weight in saline-
infused mice (4.17  0.04 mg/g vs. Ad-bgal: 3.90 
0.05mg/g; p¼NS) (Figure 3A). Treatmentwith Ad-Fstl1
also ameliorated a measure of diastolic dysfunction.
The E/A ratio was signiﬁcantly reduced with Ad-Fstl1
(1.88  0.10 vs. Ad-bgal: 1.50  0.10; p < 0.05)
(Figure 3B). Taken together, these data indicate that
treatment with Fstl1 reduces aldosterone-induced
cardiac hypertrophy both in vitro and in vivo. In con-
cert with the decreased LVH, the reduced E/A ratio also
suggests an improvement in diastolic dysfunction.
CARDIAC MYOCYTE DELETION OF Fstl1 AGGRAVATES
THE HFpEF PHENOTYPE IN MICE. To corroborate the
hypothesis that Fstl1 is an important modulator of
cardiac myocyte hypertrophy in HFpEF, we proceeded
to address this in cardiac myocyte-speciﬁc Fstl1-KO
mice (cFstl1-KO) (18). There was no detectable base-
line phenotype in cFstl1-KO mice. Both cFstl1-KO and
WT littermates underwent induction of HFpEF, and
mice were sacriﬁced at the end of 4 weeks. Mice
characteristics are summarized in Table 3.
Body weight was comparable between all experi-
mental groups. Systolic BP was measured weeklyophy Induced By Aldosterone in Adult Rat Ventricular Myocytes
NA expression in adult rat ventricular myocytes after 30-min
and 18-h treatment with 1 mmol/l aldosterone (Aldo). n ¼ 6 to 12
allis test followed by Dunn test. Abbreviations as in Figure 1.
FIGURE 3 Systemic Intravenous Delivery of Fstl1 Ameliorates Cardiac Hypertrophy and Reduces E/A Ratio in Wild-Type HFpEF Mice
(A) Heart weight/body weight ratio. (B) Ratio of peak E velocity to peak A velocity (E/A). Wild-type HFpEF (aldosterone infusion) and Sham
(saline infusion) mice were injected, 2 weeks after HFpEF induction, with an adenoviral vector producing either b-galactosidase (Ad-bgal:
1  109 plaque-forming units) as control, or Fstl1 (Ad-Fstl1: 1  109 plaque-forming units) (n ¼ 3 to 4 mice/group). Data are mean  SEM.
Statistical analysis by analysis of variance (ANOVA) followed by Newman-Keuls multiple comparison tests. Abbreviations as in Figure 1.
Tanaka et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 4 , 2 0 1 6
Fstl1 and LVH in HFpEF J U N E 2 0 1 6 : 2 0 7 – 2 1
214(Figure 4A) and was signiﬁcantly increased after 4
weeks of chronic aldosterone infusion in both WT-
HFpEF and cFstl1-KO-HFpEF mice compared with
their respective Shams (p < 0.01). There was noTABLE 3 Characteristics of WT and cFstl1-KO Mice With HFpEF—4 We
WT-Sham
(n ¼ 10)
Body weight, g 24.3  1.1
Serum aldosterone levels, pg/ml 548  65 6
Systolic blood pressure, mm Hg 120  2
Heart rate, beats/min 691  21
LV structure and systolic function
TWT, mm 0.87  0.01
LVEDD, mm 3.52  0.06
LVESD, mm 1.75  0.09
LVEF, % 82.03  1.82 8
LV diastolic function
Peak E velocity, mm/s 842.28  18.44 1,00
Peak A velocity, mm/s 661.57  16.69 70
E/A 1.28  0.03
DT, ms 21.43  0.57 2
IVRT, ms 21.07  0.64 1
Peak e0 velocity, mm/s 25.56  0.98 1
E/e0 33.16  1.04 5
Values are mean  SEM. Body weight, hemodynamic parameters, blood chemical anal
analysis of variance followed by Newman-Keuls multiple comparison tests. *p < 0.001 vs
vs. WT-HFpEF. kp < 0.05 vs. respective Sham.
A ¼ peak late transmitral ﬂow velocity; cFstl1-KO ¼ follistatin-like 1 cardiac myocyte-s
velocity; e0 ¼ peak early diastolic mitral annular velocity; E/A ¼ the ratio of peak E velocit
WT ¼ wild-type; other abbreviations as in Table 2.difference in systolic BP in mice with WT-HFpEF and
cFstl1-KO-HFpEF (Table 3).
As expected, chronic aldosterone infusion caused
HFpEF and resulted in cardiac hypertrophy, aseks After Chronic Aldosterone (HFpEF) and Saline (Sham) Infusion
WT-HFpEF
(n ¼ 12)
cFstl1-KO-Sham
(n ¼ 10)
cFstl1-KO-HFpEF
(n ¼ 12)
25.2  1.0 25.0  1.7 26.5  1.8
,326  401* 575  71 5,990  325*
139  4† 116  4 138  5†
702  13 694  17 669  23
1.11  0.02† 0.90  0.01 1.27  0.02†‡
3.28  0.13 3.43  0.10 3.35  0.13
1.57  0.07 1.63  0.09 1.58  0.11
4.26  1.06 84.30  1.65 84.78  1.63
6.09  21.93† 834.46  36.65 1,163.30  70.20†§
7.41  17.46 634.72  16.61 656.55  24.61
1.43  0.05k 1.31  0.04 1.77  0.07†‡
0.78  0.58 21.00  0.61 18.13  0.36†§
9.53  0.33k 20.45  0.74 13.75  0.51†‡
9.27  0.28† 25.58  1.13 16.57  0.50†‡
2.29  1.34† 32.68  1.03 70.09  2.77†‡
ysis, LV structure, and systolic and diastolic function in mice. Statistical analysis by
. respective Sham. †p < 0.01 vs. respective Sham. ‡p < 0.01 vs. WT-HFpEF. §p < 0.05
peciﬁc knockout; DT ¼ early ﬁlling deceleration time; E ¼ peak early transmitral ﬂow
y to peak A velocity; IVRT ¼ isovolumetric relaxation time; TWT ¼ total wall thickness;
FIGURE 4 HFpEF Is Aggravated in Cardiac Myocyte-Speciﬁc Fstl1 KO Mice
(A) Tail cuff systolic blood pressure (BP) recorded weekly for 4 weeks in wild-type (WT) and cFslt1-KO mice infused with aldosterone (HFpEF)
or saline (Sham) (n ¼ 10-12 mice per group). (B) Heart weight/body weight ratio and (C) wet lung/dry lung ratio in WT and cardiac myocyte-
speciﬁc Fstl1 knockout (cFslt1-KO) mice (n ¼ 5 to 10 mice/group). Diastolic function assessed 4 weeks after aldosterone (HFpEF) or saline
(Sham) infusion in WT and cFslt1-KO mice (n ¼ 10 to 12 mice/group). (D) Representative pulse wave and tissue Doppler images. (E) Left
ventricular compliance measured as ratio of peak E velocity to peak A velocity (E/A), and (F) diastolic ﬁlling pressure evaluated as ratio of peak
E velocity to peak é velocity. Data are mean  SEM. Statistical analysis by analysis of variance followed by Newman-Keuls multiple comparison
tests. A ¼ peak late transmitral ﬂow velocity; E ¼ peak early transmitral ﬂow velocity; é ¼ peak early diastolic myocardial velocity; other
abbreviations as in Figure 1.
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216measured by an increase in the heart weight to
body weight ratio, in WT mice versus respective
saline-infusion control mice (5.56  0.14 mg/g vs. 4.46
 0.11 mg/g; p < 0.0001). Cardiac hypertrophy was,
however, greater in cFstl1-KOmice with HFpEF (6.14
0.23 mg/g) than in WT-HFpEF mice (p < 0.05)
(Figure 4B). Consistent with these ﬁndings, total wall
thickness, determined by echocardiography, was also
increased in both groups of aldosterone-infused mice,
but increased more in cFstl1-KO-HFpEF than WT-
HFpEF. There were no differences in LVEDD and LV
end-systolic diameter between the experimental
groups of mice (Table 3).
Both WT-HFpEF and cFstl1-KO-HFpEF mice had a
normal LVEF but demonstrated pulmonary conges-
tion. However, there was more lung congestion in
cFstl1-KO-HFpEF than WT-HFpEF mice, as measured
by an increase in the wet-to-dry lung weight ratio
(4.57  0.07 vs. 4.37  0.05; p < 0.01) (Figure 4C).
Mitral Doppler analysis (Table 3, Figure 4D) showed
an increased peak E-wave velocity in both groups of
HFpEF mice (p < 0.01 vs. respective sham groups).
The peak E-wave velocity in cFstl1-KO-HFpEF mice
was, however, signiﬁcantly higher than in WT-
HFpEF mice (p < 0.05). Because the peak A-wave
velocity remained comparable in all groups of mice,
the resultant E/A ratio was higher in aldosterone-
infused mice, with the greatest increase in the
cFstl1-KO-HFpEF mice (p < 0.01 vs. WT-HFpEF)
(Figure 4E). These results suggest worse LV compli-
ance in cFstl1-KO-HFpEF versus WT-HFpEF mice.
Moreover, deceleration time was shortened in
cFstl1-KO-HFpEF versus WT HFpEF (p < 0.05),
implying more impaired LV relaxation. Similar to
humans, in whom isovolumetric relaxation time
(IVRT) initially increases with impaired relaxation
but then decreases with progressive worsening of
diastolic function, IVRT was signiﬁcantly shorter
both in mice with WT-HFpEF and with cFstl1-KO-
HFpEF (p < 0.05 vs. respective Shams). Moreover,
cFstl1-KO-HFpEF mice also showed diminished IVRT
when compared with WT-HFpEF mice (p < 0.01).
Tissue Doppler was used to measure mitral annular
e0 velocity (Table 3). Aldosterone infusion decreased
the peak mitral é velocity in mice with WT-HFpEF
(p < 0.01 vs. WT-Sham) and was further reduced
in cFstl1-KO-HFpEF versus WT-HFpEF mice (p <
0.01). Thus, the resultant E/e0 ratio, a measure of dia-
stolic ﬁlling pressure, was higher in mice with cFstl1-
KO-HFpEF when compared with mice with WT-
HFpEF (p < 0.01) (Figure 4F).
In summary, these ﬁndings indicate that lack of
Fstl1 expression in cardiac myocytes exacerbates
diastolic dysfunction in mice with HFpEF.HFpEF EXACERBATION IN cFstl1-KO MICE IS ASSOCIATED
WITH CARDIAC MYOCYTE HYPERTROPHY. We next
investigated whether the increase in cardiac hyper-
trophy and exacerbation of HFpEF in cFstl1-KO were
also associated with cellular changes, as seen in
ARVM.
Histological examination of the LV showed that
cardiac myocyte hypertrophy, as measured by cardiac
myocyte size, was signiﬁcantly greater in cFstl1-
KO-HFpEF than WT-HFpEF and Sham controls
(cFstl1-KO-HFpEF: 341.2  8.5 mm2 vs. WT-HFpEF:
309.4  13.4 mm2; p < 0.05) (Figure 5A). Further-
more, ANP and BNP mRNA expression were increased
in both groups of HFpEF mice (p < 0.0001 vs. Sham),
but the increase was signiﬁcantly higher in cFstl1-KO-
HFpEF versus WT-HFpEF mice (p < 0.05) (Figure 5B).
These data supported earlier ﬁndings in ARVM indi-
cating that Fstl1 plays a role in cardiac myocyte hy-
pertrophy. Thus, although treatment with Fstl1
modulates cardiac growth in response to cell stress,
deﬁciency of Fstl1 in cardiac myocytes induces more
hypertrophy in HFpEF mice.
Fstl1 DELETION DOES NOT AFFECT THE CARDIAC
FIBROTIC PHENOTYPE. Cardiac hypertrophy and
myocardial ﬁbrosis are commonly seen in the hearts
of patients with HFpEF (4) and may be related to
comorbidities other than HTN (34). An increase in the
collagen content in the myocardium results in
myocardial ﬁbrosis, which is considered an endpoint
in the pathological process of cardiac remodeling,
leading to impaired ventricular function. Thus, the
presence of diffuse myocardial ﬁbrosis could be a
major determinant of altered diastolic ﬁlling and
systolic pumping function in the LV (35). We next
examined whether deletion of Fstl1 in cardiac myo-
cytes affected myocardial ﬁbrosis in HFpEF. Using
Masson trichrome staining to quantify collagen
deposition we found that, as expected, aldosterone
infusion signiﬁcantly increased the area of myocar-
dial ﬁbrosis in both groups of mice (p < 0.05 vs.
respective saline), but was not different between
cFstl1-KO-HFpEF and WT-HFpEF mice (3.8  0.9% vs.
2.9  0.8%) (Figure 6A). Similarly, collagen 1 and 3
mRNA expression were signiﬁcantly higher versus
Sham (p < 0.05) but were comparable between cFstl1-
KO-HFpEF and WT-HFpEF mice (Figure 6B).
These results indicate that Fstl1 plays a pivotal role
in cardiac hypertrophy during HFpEF independent of
changes in ﬁbrosis.
DISCUSSION
The prevalence of HFpEF continues to increase, but
prognosis remains poor. Patients with HFpEF have an
FIGURE 5 Lack of Fstl1 Increases Cardiac Myocyte Hypertrophy in HFpEF Mice
(A) Cardiac myocyte hypertrophy in the left ventricle (LV) (left, representative hematoxylin and eosin images, scale bar: 10 mm) and
quantitative measure of cardiac myocyte cross-sectional area (right). (B) Atrial natriuretic peptide (ANP) and brain natriuretic peptide
(BNP) mRNA expression in WT and cFslt1-KO mice with aldosterone (HFpEF) or saline (Sham) infusion. n ¼ 6 to 12 mice/group. Data are
mean  SEM. Statistical analysis by analysis of variance followed by Newman-Keuls multiple comparison tests. Abbreviations as in
Figures 1 and 4.
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217impressive 5-year mortality rate (approaching 60%)
and a costly morbidity rate, with approximately 50%
of patients being readmitted to the hospital within 6
months (36). Predictors of morbidity and mortality in
HFpEF remain incompletely deﬁned (37). In addition,
to date, standard HF therapy shown to be effective in
HFrEF have no established beneﬁt in HFpEF (38). In
fact, recently published HF guidelines concluded that
“no treatment has yet been shown, convincingly, to
reduce morbidity or mortality in patients with
HFpEF” (39).
In search of potential novel therapies for HFpEF, the
goal of this study was to investigate the role of Fstl1 in
HFpEF. Fstl1 levels weremeasured in a cohort of stableHFpEF patients and were signiﬁcantly increased
compared with control subjects. Similarly, in vitro and
in vivo studies showed increased expression of Fstl1 in
cardiac myocytes when ARVM were stimulated with
aldo and in a murine model of HFpEF. Deletion of Fstl1
in cardiac myocytes exacerbated cardiac hypertrophy
inHFpEF, independent ofﬁbrosis. These changeswere
accompanied by increased gene expression of natri-
uretic peptides (ANP and BNP), molecular markers of
cardiac myocyte hypertrophy.
In addition to elevated circulating levels of Fstl1 in
HF, elevated levels are also seen in acute coronary
syndrome (14,40), indicating the importance of this
cardiokine in cardiac disease. Murine models of
FIGURE 6 Lack of Cardiac Myocyte Fstl1 in HFpEF Does Not Affect Cardiac Fibrosis
(A) Cardiac ﬁbrosis in the left ventricle (LV) (left, representative Masson trichrome images, original magniﬁcation 400) and myocardial
ﬁbrosis area (right) in WT and cFslt1-KO mice subjected to aldosterone (HFpEF) or saline (Sham) infusion. (B) Collagen 1 and 3 mRNA
expression in WT and cFslt1-KO mice after aldosterone (HFpEF) or saline (Sham) infusion. n ¼ 6 to 12 mice/group. Data are mean  SEM.
Statistical analysis by analysis of variance followed by (A) Newman-Keuls multiple comparison tests and (B) Kruskal-Wallis test followed
by Dunn test.
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218cardiac stress, such as myocardial pressure overload
or ischemia and reperfusion injury, have also shown
increased cardiac expression of Fstl1 (18,41). It has
been suggested that cardiac myocytes are a major
source of Fstl1 (42) and that cardiac expression of
Fstl1 mediates a protective effect via different
mechanisms such as antiapoptotic or anti-
hypertrophic actions (18,41). In the present study,
therapy with rFslt1 demonstrated an antihypertrophic
response in cardiac myocytes stimulated with path-
ophysiological doses of aldosterone (30). In this
chronic aldosterone infusion HFpEF model, circu-
lating levels of aldo are in the range of 6 to 7.5 nmol/l
(16,17), which is comparable to levels (w100 nmol/l)seen in acute human HF (43–45). Similar to in vitro
ﬁndings, treatment with Ad-Fstl1 abrogated cardiac
hypertrophy in mice with HFpEF.
Cardiac-speciﬁc myocyte deletion of Fstl1 in mice
with HFpEF was also associated with marked LVH.
This LVH was accompanied by a worsening of dia-
stolic dysfunction as determined by echocardiogra-
phy. These changes were not associated with changes
in systolic BP. In the present study, cardiac myocyte
deletion of Fstl1 did not affect BP regulation. There-
fore, the observed increase in LVH and worsened
diastolic dysfunction were direct consequences of
cardiac myocyte deletion of Fstl1-induced changes in
the heart.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The lack of
evidence-based therapies continues to hinder our care and
treatment of patients with HFpEF. Therapy has been relegated to
symptom control and the management of comorbidities, such as
HR and BP control. This is inadequate, and the increasing prev-
alence of HFpEF highlights the pressing need to identify new
mechanistic pathways to target therapy for HFpEF.
TRANSLATIONAL OUTLOOK: HFpEF is a heterogeneous
disease with associated comorbidities and risk factors. Limited
animal models of HFpEF continue to plague translational studies,
and utilizing a murine model may not be entirely complementary
to human cardiac disease. However, identifying factors present in
patients with HFpEF (such as Fstl1) and exploring the relevance
of these factors in a murine model of HFpEF indicate that Fstl1
and its role in cardiac hypertrophy is not a model-speciﬁc ﬁnding
and may contribute to our understanding of the pathogenesis of
HFpEF for future drug development. These pre-clinical studies
are important not only to test drug therapies, but also to provide
insights into signaling pathways important in the pathogenesis of
HFpEF.
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219HFpEF is a disease and clinical syndrome that is
associated with different comorbidities and patho-
physiologies. The latter includes structural, func-
tional, and metabolic abnormalities (46). LVH is the
most common myocardial structural abnormality
associated with HFpEF (47). A broad range of mo-
lecular pathways are thought to be involved in the
development of cardiac hypertrophy, including the
release of hormones, cytokines, chemokines, and
peptide growth factors (48,49). cFstl1-KO mice with
HFpEF displayed a greater increase in cardiac
myocyte hypertrophy versus WT-HFpEF mice. In
addition, increases in ANP and BNP expression were
greatest in HFpEF when there was cardiac myocyte-
speciﬁc deletion of Fstl1. The molecular mecha-
nisms of Fstl1 in cardiac function and hypertrophy
in HFpEF are not fully understood. A major unan-
swered question is how Fstl1 regulates cardiac
myocyte hypertrophy. It has been demonstrated
that Akt signaling pathway induces Fstl1 up-
regulation in the heart during cardiac injury (12)
and that Fstl1 promotes AMPK activation, which
may function by suppressing cardiac hypertrophy
(18).
Increased cardiac myocyte growth is usually
accompanied by an increase in the extracellular ma-
trix, which is predominantly composed of collagen
and, to a lesser degree elastin, laminin, and ﬁbro-
nectin (50). The present ﬁndings differ from prior
reports that suggested Fstl1 plays a role by modu-
lating cardiac (18), renal (42), or pulmonary (51)
ﬁbrosis. The observed differences could be due to
the experimental model used in the different studies.
For example, Shimano et al. (18) utilized a model of
pressure overload induced by transverse aortic
constriction over 4 weeks in cFstl1-KO, which resul-
ted in HFrEF with depressed LVEF and a dilated LV
chamber size. These data suggest that there is dif-
ferential regulation of Fstl1 in cardiac myocyte hy-
pertrophy in HFpEF versus HFrEF.
LVH regression is not always accompanied by
improvement in parameters of diastolic dysfunction
(52), and conversely, improvement in diastolic
dysfunction parameters is not consistently accompa-
nied by LVH regression (15). In the present study,
mice with HFpEF, that lack cardiac myocyte-speciﬁc
Fstl1 showed exacerbation of LVH that was accom-
panied by worsening of diastolic dysfunction.
Fstl1 displays a Janus-like role in inﬂammation.
Pro-inﬂammatory actions of Fstl1 are seen in several
chronic disorders such as rheumatoid arthritis, ul-
cerative colitis, and obesity (11,53,54). Conversely theanti-inﬂammatory role of Fstl1 has also been
described in vascular, myocardial, and renal injury
models (26,41,42). Moreover, it is unknown whether
inﬂammation plays a key role in HFpEF or is simply a
bystander because of various comorbidities (55). Is
inﬂammation up-regulated in a compensatory
manner, or is it an epiphenomenon of a catabolic state
caused by HF (56)? In this study, the immunomodu-
latory role of Fstl1 in the pathophysiology of LVH in
HFpEF was not addressed.
Therefore, we conclude that Fstl1 exerts thera-
peutic effects in HFpEF by modulating cardiac hy-
pertrophy. Although there is some knowledge of the
pathophysiology and mechanisms of HFpEF, few
signaling targets have been identiﬁed. The present
work represents a “proof-of-concept” study for the
role of Fstl1 in HFpEF. We provide cell, animal, and
human data to support our hypothesis. The relevance
of these translational ﬁndings indicates that Fstl1 has
an antihypertrophic effect in HFpEF.
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